ZFIN ID: ZDB-FIG-201117-3
Farr et al., 2020 - A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy. Skeletal muscle   10:29 Full text @ Skelet Muscle
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Antibody:
Fish:
Condition:
Stage: Day 4
PHENOTYPE:
Fish:
Condition:
Observed In:
Stage: Day 4

Fig. 7-1 Oxamflatin and salermide have dose-dependent effects, independent of dystrophin expression. a Graph of average normalized pixel intensities for treatments of dmd mutants with doses of oxamflatin and salermide. Control treatment is 1% DMSO. Chemicals were used between 0.5 μM and 4 μM, over two separate experiments. For each treatment condition, n = 4 replicates, with 2-11 dmd−/− embryos in each replicate. Plot shows the average normalized pixel intensity for each of the 4 replicate pools for each treatment. The vertical line separates the treatment conditions from the two experiments, each of which has its own WT + DMSO and dmd + DMSO controls. The dashed lines represent the average normalized pixel intensity for all of the DMSO-treated dmd animals (n = 26 and n = 30). Error bars represent standard error. Significance was determined using a one-way ANOVA test comparing each treatment group to the dmd DMSO control group with Dunnett’s correction for multiple comparisons. *p ≤ 0.029, **p = 0.0029, ***p = 0.0007 compared to dmd DMSO control. b-e Confocal images of anti-dystrophin staining in the trunk musculature of 4 dpf b WT + DMSO, c WT + oxamflatin and salermide, d dmd + DMSO, and e dmd + oxamflatin and salermide larvae. Lateral views, anterior to the left. Arrow points to dystrophin expression in the vertical myoseptum. All dmd+/+ animals showed normal dystrophin expression (WT + DMSO, n = 16; WT + ox+sal, n = 14) and all dmd−/− animals lacked detectable dystrophin expression (dmd−/− + DMSO, n = 23; dmd−/− + ox+sal, n = 18). Scale bar = 50 μm. f-i Confocal images of anti-β-dystroglycan (βDG) and phalloidin staining in the trunk musculature of 4 dpf f WT + DMSO, g WT + oxamflatin and salermide, h dmd + DMSO, i dmd + oxamflatin and salermide. Lateral views, anterior to the left. Arrow points to βDG expression (white) in the vertical myoseptum. Phalloidin staining of filamentous actin (magenta) shows the disrupted muscle structure in dmd mutants (* in h). All wild type animals (+/+ and +/−) showed normal β-dystroglycan expression (WT + DMSO, n = 27; WT + ox+sal, n = 26), and dmd−/− animals showed largely maintained β-dystroglycan expression (dmd−/− + DMSO, n = 9; dmd−/− + ox+sal, n = 14). Scale bar = 50 μm

Gene Expression Details No data available
Antibody Labeling Details
Antibody Assay Fish Conditions Stage Qualifier Anatomy
Ab1-dmd IHC dmdta222a/ta222a standard conditions Day 4 Not Detected trunk musculature
IHC dmdta222a/ta222a chemical treatment by environment: 5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide, chemical treatment by environment: N-[3-[(2-oxo-1-naphthalenylidene)methylamino]phenyl]-2-phenylpropanamide Day 4 Not Detected trunk musculature
Phenotype Details
Fish Conditions Stage Phenotype
dmdta222a/ta222a standard conditions Day 4 trunk musculature ab1-dmd labeling absent, abnormal
dmdta222a/ta222a chemical treatment by environment: 5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide, chemical treatment by environment: N-[3-[(2-oxo-1-naphthalenylidene)methylamino]phenyl]-2-phenylpropanamide Day 4 trunk musculature ab1-dmd labeling absent, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Skeletal muscle for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Skelet Muscle